FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
NEW YORK, Jan. 08, 2016 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Osiris Therapeutics, Inc. (NASDAQ:OSIR) securities from May 12, 2014 through November 20, 2015, all dates inclusive (the “Class Period”) of the important January 22, 2016 lead plaintiff deadline in the class action filed by the firm. The lawsuit seeks to recover damages for Osiris investors under the federal securities laws.
To join the Osiris class action, go to the firm’s website at http://rosenlegal.com/cases-786.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll free at 866-767-3653 or email [email protected] or [email protected] for more information on the class action. The case is pending in the U.S. District Court for the Southern District of New York.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Osiris improperly recognized revenue under contracts it had with its distributors; (2) Osiris’ disclosure controls and procedures were not effective as of December 31, 2014, March 31, 2015, and June 30, 2015; and (3) as a result, defendants’ statements about Osiris’ business and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 22, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://rosenlegal.com/cases-786.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
